PS www.ProStocks.com
|
|
Zydus Lifesciences Limited is a leading Indian Pharmaceutical company that offers healthcare services globally. The company manufactures formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products as well as wellness products.
Zydus Lifesciences Limited has more than 30 manufacturing plants worldwide including India, Germany, Brazil & USA. Zydus Lifesciences Limited is the fourth largest pharmaceutical company in India. Zydus Lifesciences was formerly known as Cadila Healthcare Limited.
| Issue Period | Jun 23, 2022 - Jul 6, 2022 |
| Security Name | Zydus Lifesciences Limited |
| Issue Type | Tender Offer |
| Issue Size (Shares) | 11,538,461.00 |
| Issue Size (Amount) | ₹750.00 Crores |
| Buyback Price | ₹650 per share |
| Face Value | ₹1 per share |
| Listing At | BSE, NSE |
| Record Date | Jun 2, 2022 |
| Offer Opens On | Jun 23, 2022 |
| Last Date for receipt of Tender Forms | Jul 6, 2022 |
| Offer Closes On | Jul 6, 2022 |
| Finalisation of Buyback Acceptance | Jul 14, 2022 |
| Last Date for settlment of bids | Jul 15, 2022 |
| Last Date for Extinguishment of Shares | Jul 22, 2022 |
| Category | Entitlement Ratio of Buyback |
|---|---|
| Reserved Category for Small Shareholders | 26 Equity Share out of every 503 Fully paid-up Equity Shares held on the Record Date. |
| General Category for all other Eligible Shareholders | 1 Equity Shares out of every 101 Fully paid-up Equity Shares held on the Record Date. |
| Particulars | For the year/period ended (Rs. in Million) | ||
|---|---|---|---|
| 31-Mar-22 | 31-Mar-21 | 31-Mar-20 | |
| Total Income | 1,54,899 | 1,51,394 | 1,43,670 |
| Profit After Tax | 23,726 | 21,850 | 12,044 |
| Net Worth | 1,69,996 | 1,29,923 | 1,03,757 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Apr-2022 | 376.60 | 337.70 | 359.37 |
| Mar-2022 | 379.00 | 331.00 | 359.62 |
| Feb-2022 | 420.50 | 343.00 | 385.95 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Apr-2022 | 376.70 | 337.55 | 359.43 |
| Mar-2022 | 378.60 | 331.55 | 359.63 |
| Feb-2022 | 420.55 | 342.85 | 385.99 |
The buyback is being undertaken for the following reason:
1. The Buyback will help the Company to distribute a part of the surplus cash to its shareholders holding Equity Shares thereby, optimizing returns to the shareholders and enhancing the overall shareholders' value in longer term and improving the return on equity.
45 4.3 Rating:  Vote Here ... |
Sorry, we couldn't find any reviews, please check back later.
Zydus Lifesciences Limited
Zydus Corporate Park, Scheme No. 63,
Khoraj (Gandhinagar), 536, Sarkhej-Gandhinagar Hwy
Near Vaishnodevi Circle, Ahmedabad, 382481
Phone: +91-79-71800000
Email: dhavalsoni@zyduslife.com
Website: https://www.zyduslife.com/index
Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai - 400083
Phone: +91-22-4918 6270
Email: zyduslife.buyback2022@linkintime.co.in
Website: https://linkintime.co.in/
Lead Manager(s)
Registered Broker
The Zydus Lifesciences Buyback opens on Jun 23, 2022, and closes on Jul 6, 2022.
The Zydus Lifesciences Buyback last day to buy is not available as of now.
The Zydus Lifesciences Buyback is a Tender Offer.
Zydus Lifesciences Buyback Schedule
| Buyback Opening Date | Jun 23, 2022 |
| Buyback Closing Date | Jul 6, 2022 |
| Last Date for receipt of Tender Forms | Jul 6, 2022 |
| Finalisation of Buyback Acceptance | Jul 14, 2022 |
| Last Date for settlment of bids | Jul 15, 2022 |
| Last Date for Extinguishment of Shares | Jul 22, 2022 |
The Zydus Lifesciences Buyback is being offered at Rs ₹650 per share per equity share.
| Category | Entitlement Ratio of Buyback |
|---|---|
| Reserved Category for Small Shareholders | 26 Equity Share out of every 503 Fully paid-up Equity Shares held on the Record Date. |
| General Category for all other Eligible Shareholders | 1 Equity Shares out of every 101 Fully paid-up Equity Shares held on the Record Date. |
The record date for the Zydus Lifesciences Buyback is Jun 2, 2022.
The issue size of Zydus Lifesciences Buyback is of 11,538,461.00 equity shares at ₹650 per share aggregating upto ₹750.00 Crores.
The buyback is being undertaken for the following reason:
1. The Buyback will help the Company to distribute a part of the surplus cash to its shareholders holding Equity Shares thereby, optimizing returns to the shareholders and enhancing the overall shareholders' value in longer term and improving the return on equity.
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Zydus Lifesciences Buyback offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
FREE Account Opening (₹0)
FREE Intraday Trading (Eq, F&O)
30 days brokerage free trading
Free - Relationship Manager
Free - Classroom Training
|
|
